QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: EU GVP Product- or Population-Specific Considerations I — Vaccines

Test your understanding of the concepts covered by GVP Product- or Population-Specific Considerations I: Vaccines.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which combination best supports assessment of an individual vaccine safety case?

Only the date of vaccination and the reporter's opinion on causality Vaccine, dose and schedule, route and site, timing, clinical course, history, concomitant products and alternative explanations Only the patient's age and the vaccine brand The number of similar reports without clinical information

Question 2 of 10 Several vaccines were administered during the same visit and a patient developed an adverse event. What is the most appropriate assessment approach?

Attribute the event to the vaccine administered first Attribute the event to the vaccine with the most familiar safety profile Consider all administered vaccines, their timing, known profiles, biological plausibility and available comparative evidence Exclude the case because attribution is impossible

Question 3 of 10 What is the principal purpose of an observed-to-expected analysis after vaccination?

To determine whether every reported event was caused by the vaccine To compare reported events with the number expected in a relevant population without assuming causality To replace individual case review To identify which reporter submitted the most cases

Question 4 of 10 Which statement best describes the relationship between vaccine-specific GVP guidance and the general GVP modules?

The vaccine chapter replaces all general pharmacovigilance requirements Vaccines require a completely separate pharmacovigilance system The vaccine chapter adds context and implementation considerations while the general GVP framework remains applicable The general GVP modules apply only to non-vaccine medicinal products

Question 5 of 10 Why can waning immunity be relevant to vaccine pharmacovigilance?

It changes the validity requirements for individual case safety reports It can alter breakthrough infections and the population context in which safety events are observed, linking effectiveness evidence with safety interpretation It proves that later adverse events are caused by booster doses It affects only manufacturing controls

Question 6 of 10 Which sequence best represents the conceptual vaccine pharmacovigilance lifecycle?

Communication, product withdrawal, reporting, exposure and retrospective assessment Exposure, safety information, individual and population assessment, signal prioritisation, benefit-risk evaluation, risk management and continued surveillance Clinical trial, authorisation, end of monitoring and routine use without reassessment Statistical signal, confirmed causality, product change and termination of surveillance

Question 7 of 10 A media report about a suspected vaccine risk is followed by a sharp rise in spontaneous reports. How should this trend be interpreted?

As definitive evidence that the incidence of the event has increased As irrelevant because media-stimulated reports cannot contain useful information As potentially reflecting stimulated reporting, while the cases remain relevant for assessment As proof that the media report was scientifically correct

Question 8 of 10 Which operational response best demonstrates preparedness for a rapid increase in vaccine reports?

Process cases in chronological order without triage Reduce medical review so that all cases can be closed quickly Plan intake, risk-based triage, processing resources, medical review, signal detection and escalation routes in advance Suspend reporting until the campaign ends

Question 9 of 10 A statistical disproportionality signal is identified for a serious event after vaccination. What should happen next?

The signal should immediately be communicated as a confirmed causal association The signal should be discarded unless it is supported by a randomised trial The signal should undergo clinical review and assessment using complementary evidence The vaccine should automatically be suspended

Question 10 of 10 An incorrect route of administration causes a patient harm. How should this issue generally be conceptualised?

As evidence that the authorised vaccine product is intrinsically defective As an administration error that may generate safety information and require process, training or programme corrective action As an event that cannot be relevant to pharmacovigilance As proof that all administrations of the vaccine are unsafe

Knowledge Assessment: EU GVP Product- or Population-Specific Considerations I — Vaccines

Cookie Settings